WOONSOCKET, R.I. - CVS Health (NYSE:CVS) announced a significant leadership change with David Joyner taking over as President and Chief Executive Officer, effective last Thursday. Joyner, with a 37-year background in healthcare and pharmacy benefit management, succeeds Karen Lynch. Concurrently, Roger Farah transitions from Chairman to Executive Chairman of the Board.
Joyner's previous roles include executive vice president at CVS Health and president of CVS Caremark. His experience spans across managing pharmacy services and serving on the boards of several health care companies. Farah expressed confidence in Joyner's ability to address industry challenges and advance the company's operational goals.
As part of the leadership shift, the company also provided preliminary third-quarter financial guidance, projecting GAAP diluted Earnings per Share (EPS) between $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. These figures reflect a $1.1 billion charge related to premium deficiency reserves, mainly from Medicare and Individual Exchange businesses, which reduced Adjusted EPS by $0.63. These reserves are anticipated to be largely released in the fourth quarter, positively impacting future results.
Additionally, CVS Health reported a restructuring charge of around $1.2 billion due to store closures planned for 2025 and cost reduction actions. The company's Medical Benefit Ratio for the quarter is expected to be around 95.2%, including a 220-basis point impact from the premium deficiency reserves. Investors are advised not to rely on previous guidance issued on August 7, 2024, due to ongoing elevated medical cost pressures. Further updates will be provided in the company's upcoming earnings call on November 6, 2024.
The company acknowledges Karen Lynch's contributions, particularly during the COVID-19 pandemic and her efforts in modernizing CVS Health. The preliminary financial results remain subject to completion of closing and review procedures. This announcement is based on a press release statement.
In other recent news, CVS Health has introduced several strategic changes. The company has launched SimplePay Health, a new health plan for self-insured customers, which has reportedly resulted in a 60 percent increase in the use of top-quality providers and a 12 percent reduction in total care costs. On a different note, CVS Health has decided to exit the core infusion services sector, leading to the closure or potential sale of 29 regional pharmacies.
In response to a recent survey indicating high consumer trust in pharmacists and a preference for in-person interactions, CVS Health is introducing CVS CostVantage, a new pharmacy reimbursement model. In the realm of analyst updates, Barclays (LON:BARC) has upgraded CVS Health to 'Overweight' from 'Equalweight', and TD Cowen has reaffirmed its 'Buy' rating.
Furthermore, CVS Health has performed well in the Centers for Medicare & Medicaid Services 2025 Star Ratings, with 70% of its membership enrolled in 4.5-star plans. These are among the recent developments involving CVS Health.
InvestingPro Insights
As CVS Health navigates through this significant leadership transition and faces financial challenges, InvestingPro data provides additional context to the company's current position. Despite the recent headwinds, CVS maintains a strong market presence with a market capitalization of $80.1 billion.
The company's P/E ratio of 11.27 suggests that it may be undervalued compared to industry peers. This is further supported by an InvestingPro Tip indicating that CVS is "trading at a low revenue valuation multiple." This could present an opportunity for investors looking for value in the healthcare sector, especially considering the company's robust revenue of $361.86 billion over the last twelve months.
Another InvestingPro Tip highlights that CVS "has maintained dividend payments for 54 consecutive years," showcasing the company's commitment to shareholder returns even during challenging periods. With a current dividend yield of 4.18%, CVS may be attractive to income-focused investors.
It's worth noting that InvestingPro offers 9 additional tips for CVS, providing a more comprehensive analysis for those seeking deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.